284 related articles for article (PubMed ID: 27182159)
1. Role of estrogen receptor β selective agonist in ameliorating portal hypertension in rats with CCl4-induced liver cirrhosis.
Zhang CG; Zhang B; Deng WS; Duan M; Chen W; Wu ZY
World J Gastroenterol; 2016 May; 22(18):4484-500. PubMed ID: 27182159
[TBL] [Abstract][Full Text] [Related]
2. Salvianolic acid B lowers portal pressure in cirrhotic rats and attenuates contraction of rat hepatic stellate cells by inhibiting RhoA signaling pathway.
Xu H; Zhou Y; Lu C; Ping J; Xu LM
Lab Invest; 2012 Dec; 92(12):1738-48. PubMed ID: 22986787
[TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor β selective agonist ameliorates liver cirrhosis in rats by inhibiting the activation and proliferation of hepatic stellate cells.
Zhang B; Zhang CG; Ji LH; Zhao G; Wu ZY
J Gastroenterol Hepatol; 2018 Mar; 33(3):747-755. PubMed ID: 28884481
[TBL] [Abstract][Full Text] [Related]
4. Spironolactone lowers portal hypertension by inhibiting liver fibrosis, ROCK-2 activity and activating NO/PKG pathway in the bile-duct-ligated rat.
Luo W; Meng Y; Ji HL; Pan CQ; Huang S; Yu CH; Xiao LM; Cui K; Ni SY; Zhang ZS; Li X
PLoS One; 2012; 7(3):e34230. PubMed ID: 22479572
[TBL] [Abstract][Full Text] [Related]
5. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase.
Trebicka J; Hennenberg M; Laleman W; Shelest N; Biecker E; Schepke M; Nevens F; Sauerbruch T; Heller J
Hepatology; 2007 Jul; 46(1):242-53. PubMed ID: 17596891
[TBL] [Abstract][Full Text] [Related]
6. Sodium ferulate lowers portal pressure in rats with secondary biliary cirrhosis through the RhoA/Rho-kinase signaling pathway: a preliminary study.
Wei L; Yang J; Wang M; Xu SN; Liang HM; Zhou Q
Int J Mol Med; 2014 Nov; 34(5):1257-67. PubMed ID: 25174394
[TBL] [Abstract][Full Text] [Related]
7. Increased contractility of hepatic stellate cells in cirrhosis is mediated by enhanced Ca2+-dependent and Ca2+-sensitization pathways.
Iizuka M; Murata T; Hori M; Ozaki H
Am J Physiol Gastrointest Liver Physiol; 2011 Jun; 300(6):G1010-21. PubMed ID: 21393429
[TBL] [Abstract][Full Text] [Related]
8. Terutroban, a TP-receptor antagonist, reduces portal pressure in cirrhotic rats.
Rosado E; Rodríguez-Vilarrupla A; Gracia-Sancho J; Tripathi D; García-Calderó H; Bosch J; García-Pagán JC
Hepatology; 2013 Oct; 58(4):1424-35. PubMed ID: 23703868
[TBL] [Abstract][Full Text] [Related]
9. Sodium Ferulate Reduces Portal Pressure Through Inhibition of RhoA/Rho-Kinase and Activation of Endothelial Nitric Oxide Synthase in Cirrhotic Rats.
Liu J; Peng L; Yang J; Wang M; Xu S; Liu J; Han P; He J; Tian D; Zhou Q
Dig Dis Sci; 2015 Jul; 60(7):2019-29. PubMed ID: 25724163
[TBL] [Abstract][Full Text] [Related]
10. Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis.
Klein S; Rick J; Lehmann J; Schierwagen R; Schierwagen IG; Verbeke L; Hittatiya K; Uschner FE; Manekeller S; Strassburg CP; Wagner KU; Sayeski PP; Wolf D; Laleman W; Sauerbruch T; Trebicka J
Gut; 2017 Jan; 66(1):145-155. PubMed ID: 26385087
[TBL] [Abstract][Full Text] [Related]
11. AMPK agonist AICAR ameliorates portal hypertension and liver cirrhosis via NO pathway in the BDL rat model.
Hu L; Su L; Dong Z; Wu Y; Lv Y; George J; Wang J
J Mol Med (Berl); 2019 Mar; 97(3):423-434. PubMed ID: 30721324
[TBL] [Abstract][Full Text] [Related]
12. Mitochondria-targeted antioxidant mitoquinone deactivates human and rat hepatic stellate cells and reduces portal hypertension in cirrhotic rats.
Vilaseca M; García-Calderó H; Lafoz E; Ruart M; López-Sanjurjo CI; Murphy MP; Deulofeu R; Bosch J; Hernández-Gea V; Gracia-Sancho J; García-Pagán JC
Liver Int; 2017 Jul; 37(7):1002-1012. PubMed ID: 28371136
[TBL] [Abstract][Full Text] [Related]
13. Role of beta3-adrenoceptors for intrahepatic resistance and portal hypertension in liver cirrhosis.
Trebicka J; Hennenberg M; Schulze Pröbsting A; Laleman W; Klein S; Granzow M; Nevens F; Zaagsma J; Heller J; Sauerbruch T
Hepatology; 2009 Dec; 50(6):1924-35. PubMed ID: 19842096
[TBL] [Abstract][Full Text] [Related]
14. Urotensin II receptor antagonist reduces hepatic resistance and portal pressure through enhanced eNOS-dependent HSC vasodilatation in CCl
Zhang R; Chen J; Liu D; Wang Y
Front Med; 2019 Jun; 13(3):398-408. PubMed ID: 30820806
[TBL] [Abstract][Full Text] [Related]
15. HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects.
Klein S; Van Beuge MM; Granzow M; Beljaars L; Schierwagen R; Kilic S; Heidari I; Huss S; Sauerbruch T; Poelstra K; Trebicka J
J Hepatol; 2012 Dec; 57(6):1220-7. PubMed ID: 22878469
[TBL] [Abstract][Full Text] [Related]
16. Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats.
Trebicka J; Leifeld L; Hennenberg M; Biecker E; Eckhardt A; Fischer N; Pröbsting AS; Clemens C; Lammert F; Sauerbruch T; Heller J
Hepatology; 2008 Apr; 47(4):1264-76. PubMed ID: 18318439
[TBL] [Abstract][Full Text] [Related]
17. Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats.
Brusilovskaya K; Königshofer P; Lampach D; Szodl A; Supper P; Bauer D; Beer A; Stift J; Timelthaler G; Oberhuber G; Podesser BK; Seif M; Zinober K; Rohr-Udilova N; Trauner M; Reiberger T; Schwabl P
United European Gastroenterol J; 2020 Dec; 8(10):1174-1185. PubMed ID: 32878579
[TBL] [Abstract][Full Text] [Related]
18. Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats.
Di Pascoli M; Diví M; Rodríguez-Vilarrupla A; Rosado E; Gracia-Sancho J; Vilaseca M; Bosch J; García-Pagán JC
J Hepatol; 2013 May; 58(5):904-10. PubMed ID: 23262250
[TBL] [Abstract][Full Text] [Related]
19. K⁺-channel inhibition reduces portal perfusion pressure in fibrotic rats and fibrosis associated characteristics of hepatic stellate cells.
Freise C; Heldwein S; Erben U; Hoyer J; Köhler R; Jöhrens K; Patsenker E; Ruehl M; Seehofer D; Stickel F; Somasundaram R
Liver Int; 2015 Apr; 35(4):1244-52. PubMed ID: 25212242
[TBL] [Abstract][Full Text] [Related]
20. Amelioration of carbon tetrachloride-induced cirrhosis and portal hypertension in rat using adenoviral gene transfer of Akt.
Deng G; Huang XJ; Luo HW; Huang FZ; Liu XY; Wang YH
World J Gastroenterol; 2013; 19(43):7778-87. PubMed ID: 24431897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]